Central banks
The CRO road
In just over two months all US-based hedge funds with more than 15 investors and/or $25 million under management will have their own dedicated chief compliance officer.
Prospectus prospects
The European Union's Prospectus Directive is meant to provide a single regulatory framework for structured products across Europe. Some dealers believe it is already having a positive effect on the Italian market. Others remain cynical. By John Ferry
Fed fines ABN Amro $80 million
The US Federal Reserve has ordered ABN Amro to pay $80 million in fines for lacking adequate risk management that could identify money laundering activities in its overseas branches. According to the order released on December 19, the Amsterdam-based…
Coping with complexity
The demand for risk-based technology has never been higher due to changing business practices, growing regulatory burdens and burgeoning demand for cross-asset class products. But new entrants can still gain market share in niche areas.
A conference to remember
Structured Products Europe 2005
A metamorphosis in funds
Alternative investment products: Mutual funds
Uncertainty drives US inflation market
Alternative investment products: US inflation
Playing on correlation
Alternative investment products: Commodity hybrids
2005 in review
The energy markets were a dynamic place to be in 2005, with high volatility and an explosion of new players hitting the scene. Inevitably, though, it wasn't all smooth sailing. Energy Risk looks back over the highs and lows of 2005, from the launch of…
The evolution of Asian CDOs
Structured credit
From star man to Spider-Man - The growth of intellectual property ABS
Asset-backed securities
Highly Commended: Barclays Capital's Signet Bond
Primary focus
Highly Commended: France Telecom
Primary focus
WInner: Eurocredit Opportunities I
Primary focus
Planning for disaster
SPONSORED ROUND TABLE
Bridging the Gap
Deficit Financing
A Hybrid Future?
Life Company Funding
Takaful takes root
Cover Story
RiskNews
RiskNews
Low volatility stymies OTC growth
New angles